Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NCPA To Congress: Health Reform Should Empower Community Pharmacies To Improve Patient Outcomes, Reduce Costs
National Community Pharmacists Association (NCPA) Executive Vice President and CEO, Bruce T. Roberts, RPh testified today before the U.S. House Energy and Commerce Subcommittee on Health, offering four different recommendations to strengthen a health care reform proposal currently working its way through Congress.

Staggering Cost Of Vision Loss In Canada Underscores Urgent Need For Vision Health Plan, Says New Report
Vision loss costs Canadian society a staggering $15.8 billlion per year - significantly higher than previously estimated, according to new research study released on June 23, 2009, by CNIB and the Canadian Ophthalmological Society (COS). The study"s proponents say these costs, which are expected to increase dramatically in the years ahead, underscore the urgent need for Canada to develop a comprehensive national vision health plan.
News of the day
KPBS Examines San Diego County Board Of Supervisors' Opposition To Needle Exchange Program
KPBS examines the reasons why the San Diego Board of Supervisors will not support the city"s needle exchange program, which twice weekly provides clean needles to injection drug users as part of an effort to curb the spread of HIV, Hepatitis C and other blood-borne diseases. Dianne Jacob, chair of the board, said, "I think it particularly sends a wrong message to our kids. It sends a message to our kids that as county government, if we gave out clean needles for illegal drug use, that we condone illegal drug use. And we don"t. And it"s wrong." She said government support should go toward drug use prevention and treatment. Steffanie Strathdee, head of the division of global public health at the University of California-San Diego School of Medicine, has examined several needle exchange programs across the world, and said, "It hasn"t been associated with more people starting drug use at earlier ages, etc., ò€¦ In fact, it"s consistently been associated with reductions in high-risk behavior. And so there"s really no reason not to support it on a broader scale" (Goldberg, 7/8). This series of articles was supported by a Kaiser Family Foundation mini reporting fellowship.
Endocrinology

A Phase III Alzheimer's Drug Increases Levels Of Beta Amyloid In The Brain -- But Still Provides Benefits

Surprising new insights into how a Phase III Alzheimer"s drug might work were among the advances in potential therapies targeting two abnormal brain proteins -- beta amyloid and phosphorylated tau -- that were reported today at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna. Scientists also reported on how clinicians view and treat mild cognitive impairment (MCI), a research category used to define the state between normal aging and Alzheimer"s, that is now being used widely in clinical practice. "There are now more than 26 million people living with Alzheimer"s and dementia around the world. The cost of caring for these people, and those who will get it in the next few years, will bankrupt the world"s healthcare systems," said Ralph Nixon, PhD, MD, vice chair of the Alzheimer"s Association Medical & Scientific Advisory Council. "But, as these studies and many hundreds more reported at ICAD 2009 show, there is hope. There are currently dozens of drugs in clinical trials for Alzheimer"s. This, combined with advancements in diagnostic tools, has the potential to change the landscape of Alzheimer"s in our lifetime. How fast we get there depends completely on the investment in research. We need more government and private dollars for Alzheimer"s research now to capitalize on the progress we"ve made in the last decade," Nixon added. The studies reported at ICAD 2009 were: -- Sam Gandy, et al -- Dimebon(R), A Clinically Promising Drug For Alzheimer Disease, Regulates Amyloid-Beta Metabolism In Cultured Cells, In Isolated Nerve Terminals, And In The Interstitial Fluid Of The Living Rodent Brain. -- Moran Boimel, et al -- Immunotherapy Targeting Pathologically Phosphorylated Tau In A Tauopathy Mouse Model. -- Scott Roberts, et al -- Clinical Practices Regarding Mild Cognitive Impairment (MCI) Among Neurology Service Providers. The 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009) brings together more than 3,000 researchers from 70 countries to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer"s disease and related disorders. ICAD 2009 will be held in Vienna, Austria at Messe Wien Exhibition and Congress Center from July 11-16. The Alzheimer"s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer"s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer"s. For more information, visit http://www.alz.org. Alzheimer"s Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009